PT-141 vs DSIP
Head-to-head comparison of PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) and DSIP (Delta Sleep-Inducing Peptide) — benefits, dosing, side effects, research data, and where to buy.
| Property | PT-141 | DSIP |
|---|---|---|
| Category | Performance | Performance |
| Full Name | Bremelanotide (Melanocortin Receptor Agonist) | Delta Sleep-Inducing Peptide |
| Molecular Weight | 1,025.2 Da | 848.8 Da |
| Half-Life | ~2.7 hours | ~15-25 minutes |
| Amino Acids | 7 | 9 |
| Typical Dose | 1.75 mg | 100-200 mcg |
| Route | SC | SC / IV / Intranasal |
| Purity | — | — |
| Studies Count | 178 | 74 |
| Research Status | FDA Approved | Pre-clinical |
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
DSIP Benefits
- ✓Promotes deep delta wave sleep
- ✓Normalizes disrupted sleep patterns
- ✓Reduces cortisol and stress response
- ✓Pain modulating effects
- ✓Antioxidant properties
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
DSIP Dosing
Standard: 100-200 mcg SC or IV, 30-60 min before bed|Cycle: 10-14 days, 5-7 days off|Chronic insomnia: 100 mcg daily for 2-3 weeks|Can be combined with Ipamorelin pre-bed
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
DSIP Side Effects
- ⚠Common (Mild): Morning grogginess initially, mild headache
- ⚠Rare: Vivid dreams, temporary appetite changes
- ⚠Generally very well tolerated
Research Overview
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
DSIP
DSIP has moderate clinical evidence from European studies. Human trials show improved sleep quality and normalized sleep-wake cycles. Also studied for alcohol and opiate withdrawal. Unique mechanism distinct from traditional sleep aids.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.